Cardiovascular Safety of Romosozumab vs Parathyroid Hormone (PTH) Analogues for Osteoporosis Treatment: A Propensity-Score-Matched Cohort Study
An erratum to this article was published (J Clin Endocrinol Metab, 18 Feb 2025 ↗)
Authors' conclusion
In a diverse, real-world setting, prescription of romosozumab for osteoporosis is associated with fewer adverse CV events when compared to PTH analogue therapy.
Study context
- Population
- Patients aged ≥40 years with osteoporosis prescribed romosozumab or a PTH analogue, August 2019 through August 20225,610 per group after matching
- Participants
- 5,610 vs 5,610
- Exposure
- Romosozumab vs PTH analogue
- Romosozumabn = 5,610
- PTH analoguen = 5,610reference
- Outcome
- Incident 3-point MACE or death (3P-MACE)
- Follow-up
- 1 year after initial prescription
Methodological detailspropensity-score matched 1:1, TriNetX global federated health research network, 113 health care organizations, 16 countries, Before matching: 5626 romosozumab and 15 986 PTH analogue patients
- Propensity-score matched 1:1
- TriNetX global federated health research network
- 113 health care organizations, 16 countries
- Before matching: 5626 romosozumab and 15 986 PTH analogue patients
Main finding
As reported in the abstract
3P-MACE · 1 year
Romosozumab
158
events
PTH analogue
211
events
P = 0.003
Observational data: associations, not effects.
Further findings
Events
| Outcome | Romosozumab | PTH analogue | P value |
|---|---|---|---|
| Myocardial ischemic events · 1 year | 31 | 58 | P = 0.003 |
| Cerebrovascular events · 1 year | 56 | 79 | P = 0.037 |
| Deaths · 1 year | 83 | 104 | P = 0.099 |
Original publication
Cardiovascular Safety of Romosozumab vs PTH Analogues for Osteoporosis Treatment: A Propensity-Score-Matched Cohort Study. J Clin Endocrinol Metab. Published 14 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →